Shilpa Medicare Posts Record Revenue & EBITDA in 2QFY27, Total Income Surges 45% YoY
Shilpa Medicare reported record 2QFY27 revenue of ₹538 crore (up 45% YoY) and EBITDA of ₹151 crore (up 37% YoY). 1HFY27 income crossed ₹1,000 crore, reaching ₹1,007 crore (up 44% YoY). PAT grew 80% YoY in 2QFY27 to ₹79 crore. Key drivers include strong API and Formulations segment growth, and a new partnership with Orion Corporation.
The record financial performance, substantial YoY growth, and positive outlook on product pipelines and strategic partnerships are material developments likely to significantly influence investor perception and stock performance.
The company reported record revenues and EBITDA, significant YoY growth across key financial metrics, and highlighted strategic partnerships and product pipeline advancements, indicating strong positive momentum.
Shilpa Medicare Limited announced its financial results for the quarter ended September 30, 2026 (2QFY27), reporting its highest-ever quarterly revenue and EBITDA. The company's total income reached ₹538 crore, marking a significant 45% year-on-year (YoY) increase and a 15% quarter-on-quarter (QoQ) rise.
EBITDA also hit a record high at ₹151 crore, up 37% YoY, with EBITDA margins maintained at a healthy 28%. Profit After Tax (PAT) saw a substantial jump of 80% YoY to ₹79 crore. For the first half of FY27 (1HFY27), total income crossed the ₹1,000 crore mark for the first time, reaching ₹1,007 crore, a 44% YoY growth. EBITDA for 1HFY27 grew 40% YoY to ₹290 crore, and PAT nearly doubled, increasing by 98% YoY to ₹180 crore.
The company highlighted strong performance across all verticals, with the API segment delivering its highest-ever quarterly revenue. Management commentary emphasized the resilience and breadth of the business, the progress of the novel FDF portfolio, and strategic partnerships, including an expanded collaboration with Orion Corporation for a nivolumab biosimilar in Europe. The company also noted an improvement in its CRISIL ESG score.
Key business segments contributing to the revenue include API (47% of 1HFY27 revenue), Formulations (40%), and Biologicals (12%). The API division recorded its highest-ever quarterly revenue at ₹298 crore, with growth driven by the core portfolio and specialty CDMO. The Formulations business saw revenue grow over 50% YoY, supported by niche launches and market penetration in key regions like the US and Europe. The Biologics segment is advancing its high-value biosimilars portfolio, with a partnership with Orion Corporation for a nivolumab biosimilar and progress in other novel biologic entities and ADC platforms.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.